You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases

    SBC: Eyedesis Biosciences, LLC            Topic: N

    PROJECT SUMMARY ABSTRACT Persistent disease activity PDA in spite of anti vascular endothelial growth factor VEGF therapy remains a significant clinical unmet need for patients with neovascular age related macular degeneration NVAMD The purpose of this STTR Phase I grant application is to develop novel therapies that will be effective for the treatment of PDA associated with NVAMD The cu ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Novel sanitizer against viral infections with long lasting effect

    SBC: CAMELLIX, LLC            Topic: NIAID

    Project Summary Abstract Despite mandatory use of hand sanitizer on cruise ships there are reported cruise ship onboard norovirus outbreaks in exceeded the number of norovirus outbreaks outbreaks onboard cruise ships in One of the problems of currently available alcohol based hand sanitizer is that alcohol evaporates in less than seconds after each application to a surface ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Anti CCL mAb to treat castration resistant prostate cancer

    SBC: JYANT Technologies, Inc.            Topic: 102

    Metastatic castration resistant prostate cancer CRPC PCa accounts for of PCa deaths and is associated with skeletal metastases CRPC affects patients differently making this disease difficult for physicians to provide standardized treatments with similar outcomes Docetaxel can prolong the overall survival in patients with metastatic CRPC but current therapies do not provide a cure Doce ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    Project Summary Abstract Glioblastoma GBM is the most common primary brain tumor and one of the deadliest forms of cancer Standard surgery chemotherapy and radiation fail to eliminate the infiltrative invasive cancer cells Median survival remains only months Drugs that seek out the disseminated GBM cells behind the blood brain barrier will prevent the inevitable recurrence in patients ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Polo box PLK Inhibitors Target Tumors Resistant to ATP Competitive Compounds

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    Polo like kinase PLK is a central player in regulating entry into and progression through mitosis Many studies have validated PLK as an anti tumor drug target and its inhibition is potently anti proliferative to cancer cells However recent data suggests that there are two major disadvantages of the conventional approach to blocking the kinase activity of PLK First both general kinome ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Engineering probiotics to biosynthesize natural substances for microbiome brain research

    SBC: HGG Research LLC            Topic: R

    PROJECT SUMMARY To advance microbiome brain studies the general goals of this collaborative proposal are to provide services to research community by engineering probiotics e g E coli Nissle EcN Bifidobacteria longum Lactobacillus plantarum to biosynthesize various naturally occurring chemicals as prebiotic probiotic conjugates which will be marketed as important laboratory agents ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. High throughput CRISPR Cas cell line generation using the CellRaft Array platform

    SBC: CELL MICROSYSTEMS INC            Topic: NHGRI

    Project Summary Genome editing technologies such CRISPR Cas provide a rapid and targeted means of both knocking out gene expression and knocking in gene modifications However the current workflow required for CRISPR cell line generation relies on several technologies which reduce throughput efficiency and the overall viability of genome edited cells Cell Microsystems has developed a single ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Large Scale Preparation of Natural Glycans

    SBC: Natglycan, LLC            Topic: 400

    Project Summary Abstract The two major obstacles to progress in glycomics relative to proteomics and genomics are the lack of simple robust and automated methods for determining glycan structures and for synthesis of glycans The net result of this situation is an overall lack of defined glycans for use in functional studies and for use as standards in structural analysis Significant effort has ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Artificial neural networks for high performance fully automated particle tracking analysis even at low signal to noise regimes

    SBC: AI Tracking Solutions LLC            Topic: 400

    Abstract Particle tracking PT is a powerful biophysical tool for elucidating molecular interactions transport phenomena and rheological properties in complex biological environments Unfortunately PT remains a niche tool in life and physical sciences with a limited user base in large part due to significant time and technical constraints in extracting accurate time variant positional data fr ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Developing a new therapeutic agent for retinal ciliopathies

    SBC: Rescindo Therapeutics Inc            Topic: N

    The ciliopathies are a group of andgt overlapping clinical disorders caused by defects in the primary cilium and its anchoring structure the basal body Although individually rare this group contributes significantly to the population genetic disease burden with some estimates placing their combined incidence to as much as Importantly although some ciliopathies are lethal most pat ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government